Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904

PURPOSE: The relative value of gemcitabine-based combination chemotherapy therapy and prolonged infusions of gemcitabine in patients with advanced pancreatic cancer remains controversial. We explored the efficacy and toxicity of gemcitabine administered at a fixed dose rate or in combination with ci...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kulke, Matthew H., Tempero, Margaret A., Niedzwiecki, Donna, Hollis, Donna R., Kindler, Hedy L., Cusnir, Michael, Enzinger, Peter C., Gorsch, Stefan M., Goldberg, Richard M., Mayer, Robert J.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2009
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2792952/
https://ncbi.nlm.nih.gov/pubmed/19858396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.1309
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items